* 49.2 pct of patients disease-free at 18 months
* 80 pct of patients alive 2 years after diagnosis
LOS ANGELES, June 2 A small, early-stage trial
of a therapeutic brain cancer vaccine developed by
ImmunoCellular Therapeutics Ltd IMUC.OB showed that nearly
half the patients were alive without their cancer worsening 18
months after diagnosis, the company said on Wednesday.
The Phase 1 trial from ImmunoCellular, which trades in the
over-the-counter market, involved 16 patients diagnosed with
glioblastoma multiforme, the most common and deadly form of
They were treated with ICT-107, an experimental dendritic
cell based cancer vaccine, following the standard care of
surgery, radiation and chemotherapy.
"We are targeting specific antigens that are on cancer stem
cells ... the only population of cells that can really
propagate a tumor," said Dr. John Yu, director of surgical
neuro-oncology at Cedars-Sinai Medical Center in Los Angeles
and ImmunoCellular's chief scientific officer.
A year after diagnosis, all of the patients were alive.
After two years, 80 percent of them were alive.
Historically, after a year with standard treatment, 61
percent of glioblastoma patients are alive, and 26.5 are alive
after two years, according to the company.
In the ImmunoCellular trial, median overall survival had
not yet been reached at the 26.4 months analysis point, with 12
out of 16 patients alive. Seven patients continued to live with
no disease progression.
Side effects seen in the trial included fatigue and skin
Yu said ImmunCellular is planning a mid-stage trial of the
vaccine that would include between 30 and 50 patients.
(Reporting by Deena Beasley; Editing by Steve Orlofsky)